The
Biopharmaceutical Consortium is an expert team formed in 1997 to assist life
science companies, research groups, and emerging enterprises to identify and exploit
promising breakthrough technologies, thereby contributing to the discovery and
development of new therapeutics, diagnostics, and medical devices. Its mission
is to support its members' clients in meeting the informational, technical, organizational,
strategic, and leadership challenges of the post-genomic era.
Consortium
members demonstrate expertise and historical success in:
- Strategic business planning and enterprise growth mechanisms
- Identification
of future trends in the life sciences and relevant technologies
- Design
of efficient and effective development strategies for early stage biomedical products
- Generation of grants-based seed funding for product feasibility testing
- Assessment of the therapeutic and diagnostic potential of novel science
- Effective licensing and acquisition of technologies and nascent firms
- Business development and partnering
- Corporate capitalization,
development, and governance
- Competitive assessment
- New-product
conceptualization, commercialization, and marketing
- Technology management
in life science businesses
Clients served by Consortium
members include major pharmaceutical and biotechnology companies, emerging
life science firms, research and diagnostic products companies, producers of laboratory
equipment and supplies, investors and intermediaries, and large professional service
firms.
The Consortium combines the advantages of large
and small consulting firms: expansive depth and breadth of experience without
the training and overhead burdens associated with large, relatively junior staffs.
Each engagement is strictly tailored to client needs and executed by one or more
established experts in life science management and executive counsel. Capabilities
in technology strategy and new-product commercialization distinguish the Consortium
from most management consulting firms.
For descriptions
of Biopharmaceutical Consortium member consultancies, please click
here.
If you have any questions about the
Biopharmaceutical Consortium, its services, or its member firms, please contact
Allan B. Haberman, Principal,
Haberman Associates.
